Cytokinetics (CYTK)
Cytokinetics Statistics
Share Statistics
Cytokinetics has 118.41M shares outstanding. The number of shares has increased by 3.27% in one year.
| Shares Outstanding | 118.41M |
| Shares Change (YoY) | 3.27% |
| Shares Change (QoQ) | 0.34% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 115.43M |
| Failed to Deliver (FTD) Shares | 36.04K |
| FTD / Avg. Volume | 1.98% |
Short Selling Information
The latest short interest is 14.03M, so 11.89% of the outstanding shares have been sold short.
| Short Interest | 14.03M |
| Short % of Shares Out | 11.89% |
| Short % of Float | 12.36% |
| Short Ratio (days to cover) | 11.45 |
Valuation Ratios
The PE ratio is -8.94 and the forward PE ratio is -9.17. Cytokinetics's PEG ratio is 2.56.
| PE Ratio | -8.94 |
| Forward PE | -9.17 |
| PS Ratio | 285.13 |
| Forward PS | 3.1 |
| PB Ratio | -38.91 |
| P/FCF Ratio | -13.18 |
| PEG Ratio | 2.56 |
Enterprise Valuation
Cytokinetics has an Enterprise Value (EV) of 8.7B.
| EV / Earnings | -14.76 |
| EV / Sales | 470.99 |
| EV / EBITDA | -17.63 |
| EV / EBIT | -16.23 |
| EV / FCF | -21.76 |
Financial Position
The company has a current ratio of 6.17, with a Debt / Equity ratio of -5.14.
| Current Ratio | 6.17 |
| Quick Ratio | 6.17 |
| Debt / Equity | -5.14 |
| Total Debt / Capitalization | 124.17 |
| Cash Flow / Debt | -0.57 |
| Interest Coverage | -6.2 |
Financial Efficiency
Return on equity (ROE) is 4.35% and return on capital (ROIC) is -95.75%.
| Return on Equity (ROE) | 4.35% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -95.75% |
| Revenue Per Employee | $37,096.39 |
| Profits Per Employee | $-1,183,787.15 |
| Employee Count | 498 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -44.77% in the last 52 weeks. The beta is 0.95, so Cytokinetics's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -44.77% |
| 50-Day Moving Average | 45.63 |
| 200-Day Moving Average | 51.43 |
| Relative Strength Index (RSI) | 35.74 |
| Average Volume (20 Days) | 1.82M |
Income Statement
In the last 12 months, Cytokinetics had revenue of 18.47M and earned -589.53M in profits. Earnings per share was -5.26.
| Revenue | 18.47M |
| Gross Profit | 18.47M |
| Operating Income | -536.25M |
| Net Income | -589.53M |
| EBITDA | -493.48M |
| EBIT | -536.25M |
| Earnings Per Share (EPS) | -5.26 |
Balance Sheet
The company has 94.86M in cash and 695.45M in debt, giving a net cash position of -600.59M.
| Cash & Cash Equivalents | 94.86M |
| Total Debt | 695.45M |
| Net Cash | -600.59M |
| Retained Earnings | -2.7B |
| Total Assets | 1.4B |
| Working Capital | 928.27M |
Cash Flow
In the last 12 months, operating cash flow was -395.89M and capital expenditures -3.91M, giving a free cash flow of -399.8M.
| Operating Cash Flow | -395.89M |
| Capital Expenditures | -3.91M |
| Free Cash Flow | -399.8M |
| FCF Per Share | -3.57 |
Margins
Gross margin is 100%, with operating and profit margins of -2.9K% and -3.19K%.
| Gross Margin | 100% |
| Operating Margin | -2.9K% |
| Pretax Margin | -3.19K% |
| Profit Margin | -3.19K% |
| EBITDA Margin | -2.67K% |
| EBIT Margin | -2.9K% |
| FCF Margin | -2.16K% |
Dividends & Yields
CYTK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.04% |
| FCF Yield | -8.37% |
Analyst Forecast
The average price target for CYTK is $79, which is 95.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $79 |
| Price Target Difference | 95.9% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
Stock Splits
The last stock split was on Jun 25, 2013. It was a backward split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | -1.09 |
| Piotroski F-Score | 3 |